NCT00006294View on ClinicalTrials.gov

Genetics of Hypertension Associated Treatments (GenHAT)

CompletedOBSERVATIONAL
Enrollment

37,939

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Cardiovascular DiseasesHeart DiseasesHypertensionCoronary DiseaseMyocardial Infarction
Interventions
DRUG

Chlorthalidone

participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study

DRUG

Lisinopril

participant's drug dose will be titrated from 10mg to 40mg over the course of the study

DRUG

Amlodipine

participant's drug dose will be titrated from 10mg to 40mg over the course of the study

DRUG

Doxazosin

participant's drug dose will be titrated from 2mg to 8mg over the course of the study

Trial Locations (1)

40536

University of Kentucky, Lexington

All Listed Sponsors
collaborator

University of Minnesota

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Donna Arnett, 257-5678

OTHER

NCT00006294 - Genetics of Hypertension Associated Treatments (GenHAT) | Biotech Hunter | Biotech Hunter